Olema Pharma Sets 2024 Annual Meeting Date

TL;DR

Olema Pharma's annual meeting is July 25th, vote for directors & auditors!

AI Summary

Olema Pharmaceuticals, Inc. announced on June 13, 2024, that it will hold its 2024 Annual Meeting of Stockholders on July 25, 2024. The meeting will include the election of two Class II directors, ratification of the appointment of its independent registered public accounting firm, and other business as may properly come before the meeting. The company is seeking shareholder approval for these matters.

Why It Matters

This filing signals upcoming corporate governance decisions and director elections, which can influence the company's strategic direction and leadership.

Risk Assessment

Risk Level: low — This is a routine procedural filing announcing the date of an annual shareholder meeting and the items to be voted upon.

Key Players & Entities

• Olema Pharmaceuticals, Inc. (company) — Registrant
• July 25, 2024 (date) — Annual Meeting Date
• Class II directors (other) — Director Election

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se

Filing Documents

• olma-20240613.htm (8-K) — 57KB
• 0000950170-24-073749.txt ( ) — 165KB
• olma-20240613.xsd (EX-101.SCH) — 23KB
• olma-20240613_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Olema Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024 (the "Proxy Statement"). Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number. Proposal 1—Election of Directors Final Voting Results Nominees For Withheld Broker Non-Votes Ian Clark 33,874,399 12,094,961 2,425,736 Sandra Horning, M.D. 40,102,098 5,867,262 2,425,736 Gorjan Hrustanovic, Ph.D. 44,334,757 1,634,603 2,425,736 The Company's stockholders elected each of the three nominees for Class I director to hold office until the Company's 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified. Proposal 2—Advisory Vote on Executive Compensation Final Voting Results For Against Abstain Broker Non-Votes 45,174,223 787,068 8,069 2,425,736 The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement. Proposal 3—Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results For Against Abstain 48,366,695 19,160 9,241 The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. No other matters were subm

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OLEMA PHARMACEUTICALS, INC. Date: June 14, 2024 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR